DelMar Pharmaceuticals Announces Peer-Reviewed Publication of Interim Results of Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma Multiforme Jan 29, 2020
DelMar Pharmaceuticals to Present at the LD Micro 12th Annual Main Event on December 10, 2019 Dec 3, 2019
DelMar Pharmaceuticals Presents Positive Interim Data of VAL-083 Demonstrating Favorable Outcomes In Both Recurrent and Newly-Diagnosed GBM Nov 25, 2019
DelMar Pharmaceuticals Announces Fiscal First Quarter 2020 Financial Results and Recent Corporate Updates Nov 14, 2019
DelMar Pharmaceuticals to Host Key Opinion Leader Summit on Glioblastoma Multiforme and the Potential for Treatment with VAL-083 Nov 5, 2019
DelMar Pharmaceuticals to Present Updates of Two Phase 2 Clinical Trials of VAL-083 at the 2019 Society for NeuroOncology Annual Meeting Oct 29, 2019
DelMar Pharmaceuticals to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference Oct 24, 2019
DelMar Pharmaceuticals to Present at the Inaugural MicroCap Rodeo Investor Conference on October 15, 2019 at 11:30 AM Central Time Oct 10, 2019
DelMar Pharmaceuticals Announces Fiscal Year 2019 Financial Results and Recent Corporate Updates Sep 10, 2019
